Print this page
-
NRG-GU012: Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)
Protocol: 082305Principal Investigator:
- Lara Hathout MD (Rutgers University)
Applicable Disease Sites: Kidney -
CTEP #10512: A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer
Protocol: 032309Principal Investigator:
- Salma Jabbour M.D. (Rutgers University)
Applicable Disease Sites: Lung -
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer.
Protocol: 032403Principal Investigator:
- Dylan Roden (New Jersey Medical School)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
ARAR2221: A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC)
Protocol: 112405Principal Investigator:
- Scott Moerdler M.D. (Rutgers University)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
INFORM Extended
Protocol: 042101Principal Investigator:
- Deborah Toppmeyer M.D. (Rutgers University)
Applicable Disease Sites: Breast -
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated with Chemoradiation Therapy: A Prospective Longitudinal Cohort.
Protocol: 152101Principal Investigator:
- Salma Jabbour M.D. (Rutgers University)
Applicable Disease Sites: Lung